| Name | Title | Contact Details |
|---|
Our mission at Aware Recovery Care is to help people affected by addiction “Recover Where You Live”. At Aware Recovery Care, we transform the home into a treatment center, delivering innovative addiction services to those in need, where they live. We treat addiction like a chronic illness, and our groundbreaking and evidence-based treatment approach provides comprehensive care from a multidisciplinary team of clinicians led by an Addiction Psychiatrist, a Family Systems Therapist, and a Registered Nurse. And with the help of a Certified Recovery Advisor, we help our clients learn new skills and daily habits required to maintain abstinence, while remaining amongst family and friends in their community, thereby avoiding the oftentimes difficult return home from traditional treatment options. Privacy and anonymity are respected, and dignity is preserved as we provide care that is discreet and effective. Authenticity, empathy, purpose, and thoughtfulness are at the heart of everything we do, and we seek deeply passionate people who are committed to immersing themselves in our mission. Those who are up for the task will be rewarded with rewarding mission-oriented workdays, and a voice at the table helping to build a transformational business entering a hypergrowth stage. Come join us as we create a preferred destination for top talent in the Healthcare community and set a new standard for the treatment of SUD. In early 2021, Aware received an investment by Health Enterprise Partners (HEP), a growth equity firm whose investors include some of the largest health systems and health insurance plans in the United States. Aware now operates in nine states (CT, MA, RI, NH, ME, VA, OH, IN, FL) and is poised for hyper-growth and national expansion in partnership with established national and regional payors, employers, and other stakeholders.
Metastar is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Athenahealth is a leading provider of cloud-based services for electronic health records (EHR), revenue cycle management and medical billing, patient engagement, care coordination, and population health management, as well as Epocrates and other point-of-care mobile apps.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.